Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Non-Current Assets (2022 - 2025)

Oramed Pharmaceuticals' Non-Current Assets history spans 4 years, with the latest figure at $97.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets changed N/A year-over-year to $97.6 million; the TTM value through Dec 2025 reached $97.6 million, changed N/A, while the annual FY2025 figure was $97.6 million, N/A changed from the prior year.
  • Non-Current Assets reached $97.6 million in Q4 2025 per ORMP's latest filing, up from $84.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $97.6 million in Q4 2025 to a low of $4.3 million in Q3 2022.
  • Average Non-Current Assets over 4 years is $35.2 million, with a median of $27.4 million recorded in 2022.
  • The largest YoY upside for Non-Current Assets was 1193.97% in 2023 against a maximum downside of 83.87% in 2023.
  • A 4-year view of Non-Current Assets shows it stood at $4.5 million in 2022, then skyrocketed by 1178.78% to $58.0 million in 2023, then tumbled by 61.52% to $22.3 million in 2024, then surged by 337.5% to $97.6 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Non-Current Assets are $97.6 million (Q4 2025), $84.4 million (Q3 2025), and $62.7 million (Q2 2025).